

10 October 2024

ASX Announcement

Completion of Share Purchase Plan

Highlights

- **Share Purchase Plan raises \$635,600**
- **Shortfall Placement expected to raise additional \$158,700**
- **Proceeds to fund marketing initiatives**

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) announces the close of its Share Purchase Plan (**SPP**) that was announced to the market on 12 September 2024.

The Company was pleased with the support of existing shareholders, with approximately 100 shareholders participating for a total commitment of \$635,600 under the SPP. The Company has today issued 11,556,318 fully paid ordinary shares for valid applications lodged under the SPP.

As indicated in the SPP Offer Booklet, the Company has the option to conduct a placement for any shortfall on the same terms as the SPP (**Shortfall Placement**); having proceeded with such placement, the Company has received commitments or applications from existing Firebrick shareholders for an additional \$158,700 at \$0.055 (5.5 cents). Settlement of the Shortfall Placement is expected to occur by Tuesday, 15 October 2024.

Shares under the Shortfall Placement will be issued pursuant to the Company's existing placement capacity under ASX Listing Rule 7.1A. The issue price of \$0.055 represents a 1.8% discount to the 15-day Volume Weighted Average Price of \$0.056.

"These SPP funds, amounting to approximately \$0.8 million, are on the back of the \$0.9 million we received last month in RDTI funds," said Firebrick Executive Chairman, Dr Peter Molloy. "I am pleased to say that we now have the necessary level of funding to confidently drive our planned marketing initiatives into 2025."

Use of Proceeds

Proceeds will be used:

- to fund expansion of marketing initiatives for Nasodine® Nasal Spray in Singapore and the US beyond online sales; activities may include promotion to healthcare professionals and pursuing pharmacy distribution and marketing partnerships; and
- for working capital purposes.

This announcement was authorised by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com